Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare Conference in Miami at 9:45 AM EST (3:45 PM ...

At steady-state, individual patient plasma data showed PAS-004 inhibiting phosphorylated extracellular signal-regulated kinase (pERK) at a level of 80% near Cmax. At steady-state, individual patient ...

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026. More than 21 million US adults experience a maj ...

Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations [email protected] [email protected] 857-285-5300 ...

Stronger Balance Sheet and Earnings Quality: First year of positive retained earnings as at August 31, 2025, supported by continued free cash flow generation and lower leverage. Continued Market Share ...

Interested parties can register for and access the live webcast for the conferences by visiting the “ Events ” section of the Cardiff Oncology website. The webcast replay will be available after the ...

In connection with the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and to issue non-transferrable Warrants (the " ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB. N ...

The full abstracts can be accessed via the SABCS online program.

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been randomized in ...

“We’re pleased to have completed this Tender Offer as part of our ongoing efforts to optimize Fortrea’s capital structure,” said Fortrea Chief Financial Officer Jill McConnell. “Fortrea’s funding of ...

Invivyd expects to present in vitro VBY329 data at a future medical congress. Invivyd is moving VBY329 into IND-enabling processes with a goal of IND readiness in the second half of 2026.